Equities

Shield Therapeutics PLC

STX:LSE

Shield Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)9.60
  • Today's Change-0.40 / -4.00%
  • Shares traded1.94m
  • 1 Year change209.68%
  • Beta2.7036
Data delayed at least 20 minutes, as of Feb 06 2026 16:01 GMT.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 05-Feb-26
Select bar for recommendation details.
Recommendations05-Feb-26
Buy2
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast

The 3 analysts offering 12 month price targets for Shield Therapeutics PLC have a median target of 14.69, with a high estimate of 22.77 and a low estimate of 13.96. The median estimate represents a 53.03% increase from the last price of 9.60.
High137.2%22.77
Med53.0%14.69
Low45.4%13.96

Earnings history & estimates

Shield Therapeutics PLC reported annual 2024 losses of -0.03 per share on Apr 24, 2025.
Average growth rate-61.45%
More ▼

Revenue history & estimates

Shield Therapeutics plc had revenues for the full year 2024 of 32.18m. This was 140.20% above the prior year's results.
Average growth rate+91.39%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.